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Abstract
The effects of cell-growth regulating agents of
apolipoprotein(a) [apo(a)] synthesis were examined
in human hepatocarcinoma cell lines. Among four
cell lines, apo(a) can be detected in three cell lines,
SK-HEP-1, Hep 3B and Chang cells, but can not be
detected in Hep G2 cells at the same protein
concentration.  Particularly,  SK-HEP-1  cells
synthesized the highest level among the examined
cell lines. Two cell lines, SK-HEP-1 and Hep 3B
cells  were  treated  with  several  cell-growth
regulating agents; dimethyl sulfoxide, a l l - t r a n s
retinoic acid, interleukin-6, phorbol 12-myristate 13-
acetate (PMA) and sodium butyrate. Culture media
were harvested to determine the apo(a) level which
was produced from these cells. Dimethyl sulfoxide
and retinoic acid inhibited apo(a) synthesis dose-
dependently. In both cell lines, maximum inhi-
bitions induced by dimethyl sulfoxide and retinoic
acid were observed at 2.0% and 2.0  M, respec-
tively. PMA increased apo(a) synthesis in both cell
lines. Interleukin-6 suppressed apo(a) synthesis in
dose-dependent manner and completely blocked at
2,000 U/ml in Hep 3B cells, while there was no
changes in SK-HEP-1 cells.
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Introduction
Lipoprotein(a) [Lp(a)] is composed of a low density
lipoprotein (LDL) particle and a characteristic protein
component called apolipoprotein(a) [apo(a)] which is
linked to apolipoprotein B-100 (apo B-100) by disulfide
bond. Based on the sequencing of apo(a) protein and
cDNA, the extensive homology between apo(a) and
plasminogen suggests that a high apo(a) level is a risk
factor for atherosclerosis, leading to an inhibition of
functions and generation of plasmin (Gaubatz et al. ,
1983; Utermann and Weber, 1983; McLean et al. ,
1987). Moreover, Lp(a) level in plasma has been
reported as the best predict of coronary artery re-
occlusion after balloon angioplasty (Hearn et al., 1992;
Solymoss et al., 1993). Unlike most other risk factors,
Lp(a)  level in  plasma is  not affected  by many
physiological, pharmacological or environmental
influences. However, synthesis of Lp(a) is strictly
controlled genetically (Boerwinkle et al., 1992). Under
normal conditions, its level in plasma is greatly variable
over a wide range among individuals, but is remarkably
stable in any given individual (Boerwinkle et al., 1992). 
Although the synthesis and metabolism of apo(a) is
not clear, the liver is considered to be the major site of
apo(a) synthesis (Kraft et al., 1989; Rainwater and
Lanford, 1989; Tomlinson et al., 1989). To date, no
agents have been reported to reduce the apo(a)
synthesis effectively. Except niacin, tested drugs have
failed to lower Lp(a) concentrations in plasma (Gurakar
et al., 1985).
Since Lp(a) is detected only in a few mammalian
species, primates have been the only model used to
study its synthesis (Rainwater and Lanford, 1989;
Tomlinson  et al., 1989). Recently, atherogenesis was
induced by free apo(a) and strongly enhanced by
assembly of apo(a) with apo B-100 in the transgenic
mice (Lawn et al., 1992; Callow et al., 1995). However,
there was no studies on the regulation of apo(a)
synthesis in vivo. Fortunately, most human hepato-
carcinoma cell lines can normally synthesize and
secrete the major plasma proteins; it has been well
demonstrated that some human hepatocarcinoma cell
lines could be useful models to investigate lipoprotein
synthesis  (Knowles  et  al.,  1980;  Javitt,  1990;
Mackiewicz et al., 1991; Hahn et al., 1992).
Lp(a) level in plasma is elevated in cancer patients
and Lp(a) stimulates the proliferation of human smooth
muscle cells (Wright et al., 1989; Grainger et al., 1993).
Previous studies have demonstrated that several
cytokines and sodium butyrate can regulate the
synthesis of apolipoprotein A-I (apo A-I) and apo B-100
(Kaptein et al., 1991; Ettinger et al., 1994). 
In this study, to determine whether cell-growth
regulating agents affect the rate of apo(a) synthesis,
several cell-growth regulating agents were tested in twohuman hepatocarcinoma cell lines, SK-HEP-1 and Hep
3B cells.
Materials and Methods 
Materials
Dimethyl sulfoxide, a l l - t r a n s retinoic acid, sodium
butyrate and phorbol 12-myristate 13-acetate (PMA)
were purchased from Sigma Co. (St. Louis, MO). Fetal
bovine serum was obtained from Hyclone Laboratories
(Logan, UT), and nitrocellulose membrane was
obtained from Schleicher & Schuell (Germany). Mouse
monoclonal antibody to human Lp(a) was purchased
from Boehringer Mannheim Biochemica (Germany) and
rabbit polyclonal antibody to human Lp(a) was
purchased from DAKO (Denmark).
Cell lines and culture
Human hepatocarcinoma SK-HEP-1 (ATCC HTB 52),
Hep G2 (ATCC HB 8065), Hep 3B (ATCC HB 8064)
cells and human liver Chang (ATCC CCL 13) cells
were obtained from American Type Culture Collection
(Rockville, MD). These cell lines were maintained in
RPMI 1640 medium containing 20 mM Hepes, 50 mg/ml
gentamycin, and 10 % heat-inactivated fetal bovine
serum. Cells were plated at an initial density of
351 05/ml. Experiments were carried out with a
confluent monolayer of cells 2 days after plating.
Cell stimulation, viability and protein assay
The confluent monolayer of cells was washed twice
with PBS (pH 7.2) and incubated at 37˚C with serum-
free RPMI 1640 in the presence or absence of various
agents. After 2 days, culture supernatants were
harvested and concentrated to determine the apo(a)
synthesis. Cell viability was determined by staining the
cells with 3-(4,5-dimethyl-thiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) (Mosmann, 1983). Total
protein concentration of culture supernatants was
measured with Coomassie protein assay reagent
(Pierce, Rockford, IL) using bovine serum albumin as a
standard (Bradford, 1976).
Determination of apo(a) synthesis 
For Western blot analysis, concentrated supernatants
were separated by 5-15 % gradient SDS-PAGE as
described by Laemmli (1970) and then electroblotted
onto nitrocellulose membrane. After blocking with 5 %
non-fat milk in Tris buffered saline, pH 7.5, membrane
was incubated with mouse monoclonal antibody to
human Lp(a) for 1.5 h at room temperature. Apo(a) was
visualized by enhanced chemiluminescence system
(Amersham, Buckinghamshire, U.K.) using anti-mouse
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IgG peroxidase conjugate. The amount of apo(a) was
measured by densitometry (Quick Scan, Helena,
Beaumont, TX). Apo(a) was also identified by rabbit
polyclonal antibody to human Lp(a) as described
above.
Results and Discussion
Demonstration of apo(a) synthesis in several
human hepatocarcinoma cell lines 
To test whether available hepatocarcinoma cell lines
can produce apo(a), the level of apo(a) in the culture
media was determined using monoclonal antibody to
human Lp(a). As shown in Figure 1, apo(a) but de-
tected in SK-HEP-1, Hep 3B, and Chang cells, was not
detected  in  Hep  G2  cells  at  the  same  protein
concentration. Especially, SK-HEP-1 cells produced a
high level of apo(a). Apo(a) can also be identified by
polyclonal antibody to human Lp(a) (data not shown).
The molecular size of apo(a) synthesized in these cells
was calculated to be approximately 180 kDa under
reducing condition from its electrophoretic mobility
(Figure 1).
Apo(a) migrated to a position of approximately 650
kDa by SDS-PAGE in the absence of 2-mercapto-
ethanol (Figure 2A and 2B). In addition to 650 kDa
form, 180 kDa protein was also detected in partial
reducing condition of 0.02 % 2-mercaptoethanol (Figure
2B). Based on the molecular size of apo B-100 of about
500 kDa, the difference in electrophoretic mobility
between reduced and non-reduced apo(a) shows clear
Figure 1. Expression of apo(a) in hepatoma cell lines.  Cells were plated at an initial
density of 35105/ml on a 6-well culture plate. After 2 days, media were exchanged
with serum-free RPMI 1640 and cultured for 2 days. Culture supernatants (25 mg
protein/lane) were analyzed by Western blotting. The positions of molecular weight
standards are shown on the left. Lane 1, size marker; lane 2, SK-HEP-1; lane 3, Hep
G2; lane 4, Hep 3B; lane 5, Chang cell.195 Regulation of apo(a) synthesis
(A) (B)
Figure 2. Electrophoretic patterns of apo(a) in reducing or non-reducing condition. (A)
Lp(a) and apo(a) in normal human serum (closed arrow) and cell culture supernatants
(open arrow) were analyzed by Western blotting with or without 2-mercaptoethanol.
Lane 1, size marker; lanes 2 and 5, normal human serum; lanes 3 and 6, cell culture
supernatant; lanes 4 and 7, dimethyl sulfoxide (1.0 %) treated cell culture supernatant.
(B) Cell culture supernatants were analyzed by Western blotting with various
concentrations of 2-mercaptoethanol. Lanes 1-4: 0.2, 0.02, 0.002, 0 % 2-
mercaptoethanol, respectively.
correlation with changes caused by apo B-100 binding.
These results explain that the migration rate of the non-
reduced form of apo(a) was extremely retarded by apo
B-100 binding because 180 kDa of apo(a) was bound to
apo B-100 and forms 650 kDa complex. In parallel
experiments, apo(a) from SK-HEP-1 cells treated with
tunicamycin showed identical size to that of the
untreated cells (data not shown). Apo(a) in normal
human serum can be detected at normal size with the
same monoclonal antibody. Moreover, purchased
monoclonal antibody to Lp(a) had been prepared to be
highly specific to human apo(a) and to be not reactive
to plasminogen.  
According to our results, it was suggested that 180
kDa component is the apo(a) expressed in human
hepatocarcinoma cells, which was derived from a
minimum number of kringle 4-repeats and lower
glycosylation. For further studies SK-HEP-1 and Hep
3B cells were used here because these cells produced
large amounts of apo(a) compared with other cells.
Effects of cell-growth regulating agents on
apo(a) synthesis in SK-HEP-1 and Hep 3B cells
To investigate whether cell-growth regulating agents
control the apo(a) synthesis in liver cells, culture media
were harvested from SK-HEP-1 and Hep 3B cells
treated with several agents and analyzed by Western
blot. The level of apo(a) synthesized in these cells was
not changed significantly depending on the time period
and it was stably synthesized for 2 days (data not
shown). In both cell lines, dimethyl sulfoxide and
retinoic acid markedly inhibited the apo(a) synthesis
while PMA elevated its synthesis (Figure 3). Interes-
tingly, IL-6 did not alter the apo(a) synthesis in SK-
HEP-1 cells, but completely blocked it in Hep 3B cells
(Figure 3). All agents used here induced no significant
changes in cell viability (data not shown). Total protein
level secreted in culture media was not changed with
Figure 3. Effects of various cell-growth regulating agents on apo(a) synthesis in SK-
HEP-1 (A) and Hep 3B (B) cells. The confluent monolayer of cells was treated with
indicated reagents for 48 h and the apo(a) which was expressed by the same cell
number was analyzed by Western blotting. Lane 1, untreated control; lane 2, dimethyl
sulfoxide (2.0 %); lane 3, retinoic acid (2.0 mM); lane 4 , IL-6 (2,000 U/ml); lane 5 ,
PMA (100 nM); lane 6 , sodium butyrate (2.0 mM).agents except IL-6 (data not shown). IL-6 increased
total protein 8 fold in SK-HEP-1 cells and 2.5 fold in
Hep 3B cells compared to the control level. Hence, to
exclude the effects caused by increasing the total
amount of protein, the protein secreted by same cell
number was loaded in a Western blot for further
studies.
Dose-dependent effects of dimethyl sulfoxide,
retinoic acid and IL-6 on apo(a) synthesis in
SK-HEP-1 and Hep 3B cells
In  two  cell  lines,  apo(a)  synthesis  was  dose-
dependently inhibited by dimethyl sulfoxide and retinoic
acid (Figure 4, 5A and 5B). Remarkably, dimethyl
sulfoxide and retinoic acid almost completely inhibited
apo(a) synthesis at 2.0 % and 2.0 mM, respectively
(Figure 4, 5A and 5B). In Hep 3B cells, the level of
secreted apo(a) was decreased depending on the
concentration of IL-6 (Figure 5C). Apo(a) synthesis was
markedly inhibited by 1,000 U/ml of IL-6 and almost
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completely blocked at 2,000 U/ml (98.9 %). Recent
reports demonstrated that the apo(a) gene has
functional IL-6 responsive elements in the promoter
region (Wade et al., 1993). Hence, our result suggests
that apo(a) gene expression in Hep 3B cells can be
regulated by interaction between IL-6 and control site.
By contrast, IL-6 did not inhibit apo(a) expression in
SK-HEP-1 cells. Further studies on the apo(a) gene
expression will provide more important informations to
solve the regulatory mechanism which is modulated by
the interaction between trans-acting factors and the cis
element of apo(a) gene promoter.
Numerous studies reported that dimethyl sulfoxide,
retinoic acid, sodium butyrate and PMA can regulate
cell-growth in some types of cells. In this study, apo(a)
synthesis was regulated by these agents without a
significant change in cell number. Therefore, this
suggests a possible means of lowering the apo(a) level
and solving its regulatory mechanism.
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Figure 4. Dose-dependent inhibition of apo(a) synthesis by dimethyl sulfoxide (A and
B) or all-trans retinoic acid (C) in SK-HEP-1 cells. (A) Cells were incubated with
indicated concentrations of dimethyl sulfoxide (DMSO) for 48 h and culture
supernatants were analyzed by Western blotting. (B) To determine the total apo(a)
synthesized by SK-HEP-1 cells, cells were incubated with indicated concentrations of
dimethyl sulfoxide (DMSO). After 48 h, cell lysates and culture supernatants were
mixed and analyzed by Western blotting. (C) Cells were incubated with indicated
concentrations of retinoic acid (all-trans RA) for 48 h and the culture supernatants were
analyzed by Western blotting.
Figure. 5. Dose-dependent inhibition of apo(a) synthesis by dimethyl sulfoxide
(DMSO), retinoic acid (all-trans RA) or IL-6 in Hep 3B cells. Confluent monolayer of
cells were incubated with indicated concentrations of reagent for 48 h and the culture
supernatants were analyzed by Western blotting. 197 Regulation of apo(a) synthesis
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